Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antipsychotic
Bradanicline
Другие языки:

    Bradanicline

    Подписчиков: 0, рейтинг: 0
    Bradanicline
    Bradanicline structure.svg
    Clinical data
    Other names TC-5619
    Identifiers
    • N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
    CAS Number
    PubChem CID
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C22H23N3O2
    Molar mass 361.445 g·mol−1
    3D model (JSmol)
    • C1CN2CCC1[C@@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
      (verify)

    Bradanicline (INN, code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.

    In May 2011, AstraZeneca declined to exercise its right to license the compound. In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults. It was being studied for cognitive and memory enhancement.

    Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013. It was also discontinued for ADHD.



    Новое сообщение